Birzeit Pharmaceuticals Company (PEX:BPC)
Palestine
· Delayed Price · Currency is JOD · Price in USD 3.800
+0.050 (1.33%)
At close: Apr 28, 2026
PEX:BPC Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 47.96 | 40.65 | 43.13 | 47.03 | 45.47 | Upgrade
|
| Revenue Growth (YoY) | 17.98% | -5.74% | -8.31% | 3.44% | 26.82% | Upgrade
|
| Cost of Revenue | 30.51 | 27.46 | 28.16 | 30.13 | 28.14 | Upgrade
|
| Gross Profit | 17.45 | 13.19 | 14.97 | 16.91 | 17.33 | Upgrade
|
| Selling, General & Admin | 6.52 | 5.55 | 6.94 | 7.13 | 6.84 | Upgrade
|
| Operating Expenses | 6.73 | 5.55 | 7.79 | 7.35 | 7.01 | Upgrade
|
| Operating Income | 10.72 | 7.64 | 7.18 | 9.56 | 10.31 | Upgrade
|
| Interest Expense | -0.05 | -0.03 | -0.09 | -0.11 | -0.2 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.04 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 1.87 | -0.27 | -0.34 | -1.91 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0.1 | 0.26 | 0.12 | 0.09 | Upgrade
|
| EBT Excluding Unusual Items | 12.59 | 7.48 | 7 | 7.67 | 10.26 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.06 | 2.05 | 2.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.5 | -1.43 | 0.05 | - | 0.16 | Upgrade
|
| Asset Writedown | - | - | - | -0.69 | 0.27 | Upgrade
|
| Pretax Income | 13.08 | 6.06 | 7 | 9.02 | 13.38 | Upgrade
|
| Income Tax Expense | 1.17 | 0.87 | 0.85 | 1.09 | 1.21 | Upgrade
|
| Earnings From Continuing Operations | 11.91 | 5.19 | 6.15 | 7.93 | 12.17 | Upgrade
|
| Minority Interest in Earnings | 0.04 | -0 | -0.04 | 0.01 | -0.09 | Upgrade
|
| Net Income | 11.95 | 5.18 | 6.12 | 7.95 | 12.08 | Upgrade
|
| Net Income to Common | 11.95 | 5.18 | 6.12 | 7.95 | 12.08 | Upgrade
|
| Net Income Growth | 130.54% | -15.26% | -23.05% | -34.21% | 63.91% | Upgrade
|
| Shares Outstanding (Basic) | 39 | 39 | 39 | 38 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 39 | 39 | 38 | 39 | Upgrade
|
| Shares Change (YoY) | - | - | 2.30% | -2.38% | - | Upgrade
|
| EPS (Basic) | 0.31 | 0.13 | 0.16 | 0.21 | 0.31 | Upgrade
|
| EPS (Diluted) | 0.31 | 0.13 | 0.16 | 0.21 | 0.31 | Upgrade
|
| EPS Growth | 130.54% | -15.26% | -24.77% | -32.60% | 63.91% | Upgrade
|
| Free Cash Flow | 0 | 5.43 | 8.83 | 1.62 | 2.72 | Upgrade
|
| Free Cash Flow Per Share | - | 0.14 | 0.23 | 0.04 | 0.07 | Upgrade
|
| Dividend Per Share | 0.050 | 0.050 | 0.050 | 0.100 | 0.050 | Upgrade
|
| Dividend Growth | - | - | -50.00% | 100.00% | -31.97% | Upgrade
|
| Gross Margin | 36.38% | 32.45% | 34.71% | 35.94% | 38.11% | Upgrade
|
| Operating Margin | 22.35% | 18.80% | 16.65% | 20.32% | 22.68% | Upgrade
|
| Profit Margin | 24.91% | 12.75% | 14.18% | 16.90% | 26.56% | Upgrade
|
| Free Cash Flow Margin | 0.01% | 13.37% | 20.47% | 3.44% | 5.98% | Upgrade
|
| EBITDA | 12.13 | 9.06 | 8.68 | 11.22 | 11.98 | Upgrade
|
| EBITDA Margin | 25.29% | 22.28% | 20.12% | 23.85% | 26.34% | Upgrade
|
| D&A For EBITDA | 1.41 | 1.42 | 1.5 | 1.66 | 1.66 | Upgrade
|
| EBIT | 10.72 | 7.64 | 7.18 | 9.56 | 10.31 | Upgrade
|
| EBIT Margin | 22.35% | 18.80% | 16.65% | 20.32% | 22.68% | Upgrade
|
| Effective Tax Rate | 8.97% | 14.35% | 12.09% | 12.07% | 9.05% | Upgrade
|
| Advertising Expenses | 0.08 | 0.07 | 1.28 | - | 0.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.